News Category
Telomir Pharmaceuticals' Telomir-Zn inhibits growth in human and canine osteosarcoma cell lines at low concentrations, supporting further studies that...
Dr. Wael Sakr has announced a one-time $1,000 scholarship for undergraduate pre-med students, aiming to ease financial burdens and encourage commitmen...
Creative Biolabs has broadened its single-cell RNA sequencing, single-nucleus RNA sequencing, and single-cell multi-omics services to help researchers...
A new review reveals that the tumor microenvironment actively reprograms natural killer cells into distinct subsets, offering a framework for more pre...
The September 17 virtual forum will give investors direct access to management teams from seven life sciences companies, highlighting emerging therapi...
VERAXA Biotech's appointment of Dr. Christoph Erkel as chief scientific officer underscores its commitment to advancing its BiTAC® technology and onco...
Quantum BioPharma has received FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis therapy that targets demyelinat...
Onco-Innovations' CMO discussed the company's lead drug candidate ONC010, which targets PNKP with a dual selectivity approach, and its potential to ad...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor that targets demyelination directly, has received FDA clearance to begin a ...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's progress in developing therapies to overcome cancer drug...
GeoVax supports the new global mpox vaccine stockpile initiative, emphasizing the need for diversified supply and highlighting its GEO-MVA candidate's...
VERAXA Biotech's appointment of Raju Willener as CFO brings seasoned financial leadership to support its capital strategy and advance its proprietary ...
Onco-Innovations Ltd. advances its oncology pipeline by building manufacturing capabilities, IND-enabling activities, and securing funding, positionin...
Quantum BioPharma's FDA clearance for a phase 2 trial of Lucid-MS, a first-in-class remyelinating agent, could address the unmet need in MS by potenti...
OS Animal Health's participation in the Moody Capital conference highlights its progress in developing OST-HER2 for canine osteosarcoma, underscoring ...
Researchers at Washington University School of Medicine have advanced laser interstitial thermal therapy as a minimally invasive treatment for brain c...
Quantum BioPharma's FDA clearance to test Lucid-MS in phase 2 trials marks a pivotal step toward a treatment that could protect and repair myelin in M...
NanoViricides has registered its Phase II Ebola trial for NV-387 Oral Gummies in the Democratic Republic of Congo, marking a potential advancement in ...
Quantum BioPharma's FDA clearance to begin a Phase 2 trial of Lucid-MS marks a pivotal step toward a targeted therapy for multiple sclerosis, potentia...
Recent FDA data shows youth tobacco use at record lows, while the agency's authorization of ZYN nicotine pouches with modified risk claims highlights ...
A study of over 5,600 colorectal cancer patients reveals that the timing of brain metastasis development significantly impacts survival, underscoring ...
Onco-Innovations' ONC010 progresses through preclinical development, achieving 99.3% purity and planning a First-in-Human study in Australia, highligh...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO signals a strategic move to bolster its capital strategy and advance...
OS Therapies' participation in the Moody Capital conference highlights the company's pivotal regulatory period for its lead candidate OST-HER2, with k...
A Swiss preclinical study indicates that administering immunotherapy prior to surgical resection significantly improves outcomes for glioblastoma pati...
New research from Mass General Brigham shows that minimizing radiation to the thymus during lung cancer treatment could improve outcomes, offering a n...
Salman Fazal, MD, has been named a 2026 Castle Connolly Top Doctor for the third consecutive year, highlighting his expertise in hematology and cellul...
NanoViricides is developing NV-387 as a measles treatment, with strong preclinical data and regulatory designations, and is advancing toward a Phase I...
TransCode Therapeutics' lead candidate TTX-MC138 demonstrated significant survival benefits and reduced miR-10b expression in a preclinical breast can...
An expert and a patient discuss the importance of PSMA testing in prostate cancer care, emphasizing its role in guiding treatment and empowering patie...
A nurse's personal battle with metastatic triple-negative breast cancer underscores the significance of emerging antibody-drug conjugates and patient ...
Heidelberg Pharma and Huadong Medicine have received Chinese regulatory approval to test HDP-101 in combination therapies for multiple myeloma, expand...
A peer-reviewed study published in Critical Care Medicine reveals that VolitionRx's Nu.Q NETs H3.1 biomarker independently predicts 28-day mortality a...
Novogenia AG introduces its comprehensive MGT Plus methylation test to the U.S. market, offering analysis of 27 genes across six pathways, which enhan...
Citius Pharmaceuticals, now generating revenue from its FDA-approved cancer therapy LYMPHIR, is positioning itself for growth with a late-stage pipeli...
Annovis Bio will present recent progress and upcoming milestones, including its fully enrolled Phase 3 Alzheimer's trial with expected data in 2027, h...
A new study indicates that a personalized mRNA vaccine derived from a patient's tumor tissue can prevent melanoma recurrence for years, highlighting t...
Dr. David Zelby, a Marietta prosthodontist with 40 years of experience, has been named a 2026 Castle Connolly Top Dentist, an honor reflecting peer re...
Creative Biolabs announces a webinar featuring Dr. Greg M. Delgoffe to discuss modeling T cell dysfunction in the tumor microenvironment, highlighting...
A novel T cell therapy shows promise in treating recurrent glioblastoma, a disease with limited options, potentially transforming care for patients.
VERAXA Biotech and Secarna announce promising in vitro data for their AOC collaboration, showing enhanced potency and validating the potential of targ...
VERAXA Biotech has moved its VXA-222 bispecific antibody-drug conjugate into preclinical development, signaling progress in its oncology pipeline and ...
The Keith Dagostino Scholarship for Cancer Survivors opens applications, offering financial aid to undergraduate cancer survivors nationwide, recogniz...
VERAXA Biotech's favorable Scientific Advice from Germany's Paul-Ehrlich-Institute validates its development strategy for its lead BiTAC-TCE cancer th...
VERAXA Biotech is advancing its oncology pipeline with a dual-targeting BiTAC platform designed to improve cancer therapy precision, highlighted by re...
Onco-Innovations' LOI to acquire exclusive rights to Ifowonco's oral small-molecule LAG-3 inhibitor program could position the company at the forefron...
A new study finds that nearly 80% of young adults have early stages of cardiovascular-kidney-metabolic syndrome, linked to arterial injury, emphasizin...
Quantum BioPharma's Lucid-MS aims to address progression independent of relapse activity in multiple sclerosis by targeting myelin degradation, a nove...
